Search
元素の検索
構造の検索
Thermo Scientific Chemicals
Sotalol hydrochloride, 98%
Potent beta adrenergic antagonist | CAS: 959-24-0 | C12H21ClN2O3S | 308.82 g/mol
化学物質識別子
CAS959-24-0
仕様
スペックシート
スペックシートFormWhite to pale yellow
Loss on Drying≤0.5%
Assay (unspecified)99.0 - 101.0% (Calculated on dry basis)
Sotalol hydrochloride is used as a potent beta adrenergic antagonist, prolongs the action potential and increases the refractory period. Sotalol hydrochloride is also considered a non-selective β blocker and a potassium channel blocker with an IC50 of 43 μM.
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
Applications
Sotalol hydrochloride is used as a potent beta adrenergic antagonist, prolongs the action potential and increases the refractory period. Sotalol hydrochloride is also considered a non-selective β blocker and a potassium channel blocker with an IC50 of 43 µM.
Solubility
Soluble in phosphate buffered saline, DMSO, ethanol, water, and methanol.
Notes
Keep container tightly closed. Store in cool, dry conditions in well sealed containers.
Sotalol hydrochloride is used as a potent beta adrenergic antagonist, prolongs the action potential and increases the refractory period. Sotalol hydrochloride is also considered a non-selective β blocker and a potassium channel blocker with an IC50 of 43 µM.
Solubility
Soluble in phosphate buffered saline, DMSO, ethanol, water, and methanol.
Notes
Keep container tightly closed. Store in cool, dry conditions in well sealed containers.
RUO – Research Use Only
General References:
- Ward, D.E.; Camm, A.J.; Spurrell, A.J. The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride. Clinical Cardiology. 1979, 2, (3), 185-191.
- Axel Alt.; Henrike Potthast.; Juergen Moessinger.; Barbara Sickmüller.; Helga Oeser. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Clinical Cardiology. 2004, 58, (1), 145-150.